Key facts
- It has raised $85.6M; the latest was Later Stage VC ($67.7M) in Jul 2024.
- Notable investors include High-Tech Gründerfonds, Bayern Kapital, Kurma Partners, Andera Partners, Wellington Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for SciRhom
- ·The full record, as it builds
Funding rounds
No funding rounds for SciRhom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SciRhom
Developer of therapeutic antibodies designed to improve autoimmune disease therapies. The company creates antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signalings which is crucial for protecting the skin and intestinal barriers, enabling scientists to get better treatment options for life-threatening autoimmune diseases.
- Sector
- Healthcare
- HQ
- Martinsried, Germany
- Founded
- 2016
- Employees
- 12
- Website
- scirhom.com/
- Ownership
- Privately Held (backing)
SciRhom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SciRhom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SciRhom in its N-PORT filings yet. We sweep new filings monthly.